Gout as autoinflammatory disease: New mechanisms for more appropriated treatment targets

Autoimmunity Reviews

Volumn 12, Issue 1, 2012, Pages 66-71

  Punzi, Leonardo ^a   Scanu, Anna ^a   Ramonda, Roberta ^a   Oliviero, Francesca ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoinflammatory syndromes; Gout; Hyperuricemia; Inflammasome; Monosodium urate crystals

Indexed keywords

ALLOPURINOL; CANAKINUMAB; COLCHICINE; FEBUXOSTAT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LESINURAD; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RASBURICASE; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANILAST; TUMOR NECROSIS FACTOR ALPHA; URATE;

CELL DISRUPTION; DRUG TREATMENT FAILURE; GOUT; HUMAN; HYDROGEN BOND; HYPERURICEMIA; LEUKOCYTE ACTIVATION; NEUTROPHIL; OPSONIZATION; PATTERN RECOGNITION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW; SYNOVIUM; THROMBOCYTE ACTIVATION; TREATMENT FAILURE; URIC ACID BLOOD LEVEL;

ANIMALS; GOUT; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; HYPERURICEMIA; URIC ACID;

EID: 84866845600     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.024     Document Type: Review

References (82)

1. Choi H.K., Mount D.B., Reginato A.M., American College of Physicians, American Physiological Society Pathogenesis of gout. Ann Intern Med 2005, 143:499-516.
2. Richette P., Bardin T. Gout. Lancet 2010, 375:318-328.
3. Dehghan A., Kottgen A., Yang Q., Hwang S.J., Kao W.L., Rivadeneira F., et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008, 372:1953-1961.
4. Taniguchi A., Urano W., Yamanaka M., Yamanaka H., Hosoyamada M., Endou H., et al. A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Arthritis Rheum 2005, 52:2576-2577.
5. Roddy E., Doherty M. Epidemiology of gout. Arthritis Res Ther 2010, 12:223.
6. Zhu Y., Panya B.J., Choy H.K. Prevalence of gout and hyperuricemia in the US general population. Arthritis Rheum 2011, 63:3136-3141.
7. Miao Z., Li C., Chen Y., Zhao S., Wang Y., Wang Z., et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 2008, 35:1859-1864.
8. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009, 48(Suppl. 2):ii2-ii8.
9. Rothschild B.M., Tanke D., Carpenter K. Tyrannosaurs suffered from gout. Nature 1997, 387:357.
10. Rothschild B. Contributions of paleorheumatology to understanding contemporary disease. Reumatismo 2002, 54:272-284.
11. Nuki G., Simkin P.A. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006, 8(Suppl. 1):S1.
12. Marson P., Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo 2012, 63:199-206.
13. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
14. Lottmann K., Chen X., Schädlich P.K. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep 2012, 14:195-203.
15. Choi H.K., Ford E.S., Li C., Curhan G. Prevalence of metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007, 57:109-115.
16. Ramonda R., Lo Nigro A., Modesti V., Nalotto L., Musacchio E., Iaccarino L., et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011, 10:773-778.
17. Punzi L., Podswiadek M., Sfriso P., Oliviero F., Fiocco U., Todesco S. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 2007, 6:524-528.
18. Duewell P., Kono H., Katey J., Rayner K.J., Sirois C.M., Vladimer G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
19. Oliviero F., Scanu A., Punzi L. Metabolism of crystals within the joint. Reumatismo 2012, 63:221-229.
20. Agudelo C.A., Schumacher H.R. The synovitis of acute gouty arthritis. A light and electron microscopic study. Hum Pathol 1973, 4:265-279.
21. Seegmiller J.E., Howell R.R. The old and new concepts of acute gouty arthritis. Arthritis Rheum 1962, 5:616-623.
22. Phelps P. Polymorphonuclear leukocyte motility in vitro. II. Stimulatory effect of monosodium urate crystals and urate in solution; partial inhibition by colchicine and indomethacin. Arthritis Rheum 1969, 12:189-196.
23. Matsukawa A., Yoshimura T., Maeda T., Takahashi T., Ohkawara S., Yoshinaga M. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1 beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest 1998, 78:559-569.
24. Serhan C.N., Lundberg U., Weissmann G., Samuelsson B. Formation of leukotrienes and hydroxy acids by human neutrophils and platelets exposed to monosodium urate. Prostaglandins 1984, 27:563-581.
25. Ryckman C., Gilbert C., De Medicis R., Lussier A., Vandal K., Tessier P.A. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J Leukoc Biol 2004, 76:433-440.
26. Dalbeth N., Haskard D.O. Mechanisms of inflammation in gout. Rheumatology (Oxford) 2005, 44:1090-1096.
27. Scanu A., Oliviero F., Ramonda R., Frallonardo P., Dayer J.M., Punzi L. Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor β1 in the resolution phase. Ann Rheum Dis 2012, 71:621-624.
28. McNearney T., Baethge B.A., Cao S., Alam R., Lisse J.R., Westlund K.N. Excitatory amino acids, TNF-alpha, and chemokine levels in synovial fluids of patients with active arthropathies. Clin Exp Immunol 2004, 137:621-627.
29. Schumacher H.R., Phelps P. Sequential changes in human polymorphonuclear leukocytes after urate crystal phagocytosis. Arthritis Rheum 1971, 14:513-526.
30. Shirahama T., Cohen A.S. Ultrastructural evidence for leakage of lysosomal contents after phagocytosis of monosodium urate crystals. A mechanism of gouty inflammation. Am J Pathol 1974, 76:501-520.
31. Hoffstein S., Weissmann G. Mechanisms of lysosomal enzyme release from leukocytes. IV. Interaction of monosodium urate crystals with dogfish and human leukocytes. Arthritis Rheum 1975, 18:153-165.
32. Jaques B.C., Ginsberg M.H. The role of cell surface proteins in platelet stimulation by monosodium urate crystals. Arthritis Rheum 1982, 25:508.
33. Kozin F., Ginsberg M.H., Skosey J.L. Polymorphonuclear leukocyte responses to monosodium urate crystals: modification by adsorbed serum proteins. J Rheumatol 1979, 6:519-526.
34. Scanu A., Oliviero F., Gruaz L., Sfriso P., Pozzuoli A., Frezzato F., et al. High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther 2010, 12:R23.
35. Poubelle P.E., De Medicis R., Naccache P.H. Monosodium urate and calcium pyrophosphate crystals differentially activate the excitation-response coupling sequence of human neutrophils. Biochem Biophys Res Commun 1987, 149:649-657.
36. Onello E., Traynor-Kaplan A., Sklar L., Terkeltaub R. Mechanism of neutrophil activation by an unopsonized inflammatory particulate. Monosodium urate crystals induce pertussis toxin-insensitive hydrolysis of phosphatidylinositol 4,5-bisphosphate. J Immunol 1991, 146:4289-4294.
37. Desaulniers P., Fernandes M., Gilbert C., Bourgoin S.G., Naccache P.H. Crystal-induced neutrophil activation. VII. Involvement of Syk in the responses to monosodium urate crystals. J Leukoc Biol 2001, 70:659-668.
38. Hannigan M.O., Huang C.K., Wu D.Q. Roles of PI3K in neutrophil function. Curr Top Microbiol Immunol 2004, 282:165-175.
39. de Medicis R., Lussier A., Kahan A., Tetrault L. Phagocytosis of sodium urate and calcium pyrophosphate crystals by leukocytes of gouty, pseudogouty and healthy donors. Eur J Rheumatol Inflamm 1983, 6:143-148.
40. Popa-Nita O., Marois L., Paré G., Naccache P.H. Crystal-induced neutrophil activation: X. Proinflammatory role of the tyrosine kinase Tec. Arthritis Rheum 2008, 58:1866-1876.
41. Barabé F., Gilbert C., Liao N., Bourgoin S.G., Naccache P.H. Crystal-induced neutrophil activation VI. Involvment of FcgammaRIIIB (CD16) and CD11b in response to inflammatory microcrystals. FASEB J 1998, 12:209-220.
42. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
43. Liu-Bryan R., Pritzker K., Firestein G.S., Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 2005, 174:5016-5023.
44. Chen C.J., Chen C.J., Shi Y., Hearn A., Fitzgerald K., Golenbock D., et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262-2271.
45. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
46. Scott P., Ma H., Viriyakosol S., Terkeltaub R., Liu-Bryan R. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006, 177:6370-6378.
47. Hoffman H.M., Scott P., Mueller J.L., Misaghi A., Stevens S., Yancopoulos G.D., et al. Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice. Arthritis Rheum 2010, 62:2170-2179.
48. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
49. Terkeltaub R., Sundy J.S., Schumacher H.R., Murphy F., Bookbinder S., Biedermann S., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
50. Giamarellos-Bourboulis E.J., Mouktaroudi M., Bodar E., van der Ven J., Kullberg B.-J., Netea M.G., et al. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis 2009, 68:273-278.
51. Joosten L.A., Netea M.G., Mylona E., Koenders M.I., Malireddi R.K., Oosting M., et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010, 62:3237-3248.
52. Piccini A., Carta S., Tassi S., Lasiglié D., Fossati G., Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci U S A 2008, 105:8067-8072.
53. Cassel S.L., Eisenbarth S.C., Iyer S.S., Sadler J.J., Colegio O.R., Tephly L.A., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008, 105:9035-9040.
54. Martinon F., Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004, 117:561-574.
55. Galon J., Aksentijevich I., McDermott M.F., O'Shea J.J., Kastner D.L. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 2000, 12:479-486.
56. Dinarello C.A. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med 2011, 269:16-28.
57. Terkeltaub R., Martin J., Curtiss L.K., Ginsberg M.H. Apolipoprotein B mediates the capacity of low density lipoprotein to suppress neutrophil stimulation by particulates. J Biol Chem 1986, 261:15662-15667.
58. Terkeltaub R.A., Dyer C.A., Martin J., Curtiss L.K. Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. J Clin Invest 1991, 87:20-26.
59. Burt H.M., Jackson J.K., Rowell J. Calcium pyrophosphate and monosodium urate crystal interactions with neutrophils: effect of crystal size and lipoprotein binding to crystals. J Rheumatol 1989, 16:809-817.
60. Akahoshi T., Namai R., Murakami Y., Watanabe M., Matsui T., Nishimura A., et al. Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum 2003, 48:231-239.
61. Murakami Y., Akahoshi T., Kawai S., Inoue M., Kitasato H. Antiinflammatory effect of retrovirally transfected interleukin-10 on monosodium urate monohydrate crystal-induced acute inflammation in murine air pouches. Arthritis Rheum 2002, 46:2504-2513.
62. Getting S.J., Christian H.C., Flower R.J., Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002, 46:2765-2775.
63. Landis R.C., Yagnik D.R., Florey O., Philippidis P., Emons V., Mason J.C., et al. Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum 2002, 46:3026-3033.
64. Yagnik D.R., Evans B.J., Florey O., Mason J.C., Landis R.C., Haskard D.O. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004, 50:2273-2280.
65. Lioté F., Prudhommeaux F., Schiltz C., Champy R., Herbelin A., Ortiz-Bravo E., et al. Inhibition and prevention of monosodium urate monohydrate crystal-induced acute inflammation in vivo by transforming growth factor beta1. Arthritis Rheum 1996, 39:1192-1198.
66. Govinden R., Bhoola K.D. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 2003, 98:257-265.
67. Fava R., Olsen N., Keski-Oja J., Moses H., Pincus T. Active and latent forms of transforming growth factor beta activity in synovial effusions. J Exp Med 1989, 169:291-296.
68. Punzi L., Oliviero F., Ramonda R. Transforming growth factor-beta levels in synovial fluid of osteoarthritis with or without calcium pyrophosphate dihydrate crystals. J Rheumatol 2003, 30:420.
69. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
70. Hamburger M., Baraf H.S., Adamson T.C., Basile J., Bass L., Cole B., et al. Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011, 123(6 Suppl. 1):3-36.
71. Spencer K., Carr A., Doherty M. Patient and provider barriers to effective management of gout in general practice: A qualitative study. Ann Rheum Dis 2012, 71(9):1490-1495.
72. Neogi T. Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer?. Arthritis Rheum 2010, 62:2845-2849.
73. So A., De Meulemeester M., Pikhlak A., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
74. Cronstein B.N., Molad Y., Reibman J., Balakhane E., Levin R.I., Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995, 96:994-1002.
75. Bhat A., Naguwa S.M., Cheema G.S., Gershwin M.E. Colchicine revisited. Ann N Y Acad Sci 2009, 1173:766-773.
76. Pope R.M., Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 2007, 56:3183-3188.
77. Marques-da-Silva C., Chaves M.M., Castro N.G., Coutinho-Silva R., Guimaraes M.Z. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol 2011, 163:912-926.
78. E. Pascual, F. Sivera. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment.
79. Tim L., Jansen T.L., Richette P., Perez-Ruiz F., Tausche A.-K., Guerne P.-A., et al. International position paper on febuxostat. Clin Rheumatol 2010, 29:835-840.
80. Garay R.P., El-Gewely M.R., Labaune J.P., Richette P. Therapeutic perspectives on uricases for gout. Joint Bone Spine 2012, 79:237-242.
81. Jordan K.M. Up-to-date management of gout. Curr Opin Rheumatol 2012, 24:145-151.
82. Suresh E., Das P. Recent advances in management of gout. QJM 2011, 105:407-417.